The KRT14 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the KRT14 gene in the 143B human osteosarcoma cell line. This heterogeneous cell pool lacks functional keratin 14 protein, providing a robust loss-of-function model that avoids the biases inherent in clonal selection. The polyclonal format captures a wide spectrum of editing events, ensuring representative functional analyses of KRT14-dependent processes in a malignant osteoblastic background.
The host 143B cell line is a widely used, highly metastatic human osteosarcoma model that exhibits aggressive growth, anchorage-independent proliferation, and pronounced invasive capacity. Derived from a bone tumor, 143B cells display malignant osteoblastic features and a mesenchymal phenotype, making them particularly valuable for studying cancer dissemination and epithelial-mesenchymal transition. Their genetic tractability and well-characterized behavior have established 143B as a standard platform for CRISPR-based gene editing in bone cancer research.
Keratin 14 (KRT14) is a type I intermediate filament protein that forms obligate heterodimers with its type II partner keratin 5 (KRT5) to assemble cytoplasmic filament networks essential for mechanical resilience. KRT14 expression is primarily driven by the transcription factor p63 and is modulated by upstream signaling through EGFR and Notch pathways. These keratin filaments connect to desmosomal junctions via interactions with desmoplakin, plakoglobin, and plakophilin, and to hemidesmosomes through integrin ??6??4 complexes. Consequently, KRT14 knockout disrupts these critical structural linkages, impairing cell adhesion, tissue integrity, and mechanotransduction.
In the highly metastatic 143B osteosarcoma, KRT14 knockout offers a unique model to study keratin-dependent cancer cell behavior. Although osteosarcoma cells are mesenchymal, aberrant keratin expression can occur in sarcomas and contribute to aggressive phenotypes. KRT14 disruption abolishes intermediate filament networks, compromising mechanical stress resistance, cell adhesion, and migration, thus facilitating investigation of epithelial-mesenchymal plasticity and tumor progression. The aggressive nature of 143B cells combined with KRT14 knockout makes this a relevant system for testing therapeutic interventions targeting cytoskeletal integrity in metastatic disease.
These polyclonal KRT14 knockout cells are ideally suited for studying epidermolysis bullosa simplex pathogenesis, epithelial-mesenchymal transition, and cancer invasion mechanisms. Knockout validation can be performed via immunofluorescence for KRT14 and KRT5, and western blotting for desmoplakin and plakoglobin. Functional assays including scratch wound healing, cell adhesion, and transwell migration/invasion quantify changes in motility and invasiveness. Viability assays under mechanical stress assess the cytoprotective role of keratin filaments. The polyclonal composition minimizes clonal bias. For further details, contact Ascent Research.
